Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 31,900 shares, a growth of 212.7% from the January 31st total of 10,200 shares. Currently, 0.2% of the company's shares are short sold. Based on an average trading volume of 123,000 shares, the short-interest ratio is presently 0.3 days.
Wall Street Analyst Weigh In
Separately, Research Capitl raised Theratechnologies to a "strong-buy" rating in a research note on Friday, February 14th.
Read Our Latest Report on Theratechnologies
Institutional Investors Weigh In On Theratechnologies
A number of institutional investors and hedge funds have recently made changes to their positions in THTX. Harbour Investments Inc. boosted its position in shares of Theratechnologies by 20.0% during the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock worth $159,000 after purchasing an additional 14,655 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Theratechnologies in the fourth quarter valued at $27,000. Bank of America Corp DE grew its stake in shares of Theratechnologies by 1,416.7% in the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock valued at $30,000 after buying an additional 15,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Theratechnologies in the 4th quarter valued at $33,000. Finally, Wealthspire Advisors LLC lifted its stake in Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock worth $129,000 after acquiring an additional 20,000 shares in the last quarter.
Theratechnologies Trading Down 0.9 %
THTX traded down $0.02 on Monday, hitting $1.64. The company had a trading volume of 193,262 shares, compared to its average volume of 119,143. The company's fifty day moving average price is $1.74 and its 200 day moving average price is $1.45. Theratechnologies has a 1 year low of $1.08 and a 1 year high of $2.18. The firm has a market cap of $75.18 million, a P/E ratio of -16.35 and a beta of 1.26.
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Recommended Stories
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
